Developer docs
API playgroundTry for free, no card

Search company profiles

Kinevant Sciences

Full company profile

uuid000b7p4

Namestring
Kinevant Sciences
Websiteurl
kinevant.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in New York, United States. The company is dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs, operating within the Roivant Sciences ecosystem as one of its "Vants" — a structural model designed to create agile, focused subsidiaries with aligned incentives for efficient drug development and rigorous capital allocation.

The company's core focus is the discovery and development of therapeutic candidates for rare autoimmune conditions, though specific drug candidates, mechanisms of action, target indications, or clinical trial programs are not disclosed in the available data. As a clinical-stage entity, Kinevant does not yet have commercialized products, and its underlying technology and scientific approach are not explicitly described in the input material. The company leverages the Roivant parent's technology-enabled discovery, development, and commercialization infrastructure.

Kinevant operates with a very small team of 1-10 employees, consistent with an early-stage, asset-focused development model typical of clinical-stage biotech subsidiaries. Its business model is pre-commercial, with no disclosed revenue, pricing, or customer base. Economics are expected to depend on advancing therapeutic candidates through regulatory milestones, potentially benefiting from orphan drug exclusivity given the rare disease focus. Funding flows through the Roivant parent and its capital allocation framework rather than through independently disclosed rounds.

Short descriptiontext

Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and based in New York, dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs. It operates within the Roivant Vant ecosystem.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, autoimmune disease drugs, clinical-stage biopharmaceuticals, biopharmaceutical R&D, specialty pharmaceuticals
Industry2 codes
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kinevant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for rare autoimmune diseases with significant unmet medical needs. As a subsidiary "Vant" under Roivant Sciences, it focuses its pipeline on rare autoimmune indications, leveraging Roivant's technology-enabled discovery, development, and commercialization capabilities. The company is currently pre-commercial and operates with 1-10 employees.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage biotechnology company developing inflammation and autoimmune therapeutics, including IL-36 and checkpoint agonist antibodies. Comparable in therapeutic focus area and clinical-stage development profile.

TypeDirect peer
Description

Sister Vant under Roivant Sciences focused on autoimmune diseases. Most directly comparable as it shares the same platform model, parent company, and therapeutic focus area, but operates at a more advanced stage with publicly disclosed clinical assets.

3Chemocentryx
TypeDirect peer
Description

Biopharmaceutical company focused on autoimmune and inflammatory diseases (acquired by Amgen in 2022). Comparable as a company that successfully developed and commercialized rare autoimmune disease therapeutics, illustrating a potential exit pathway for Kinevant.

TypeEmerging player
Description

Clinical-stage biotechnology company developing therapeutics for autoimmune diseases, particularly in rare endocrinology and ophthalmology. Comparable in targeting rare autoimmune indications and operating at a similar development stage.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. Comparable as a similarly-sized clinical-stage company targeting autoimmune indications with similar binary risk profile.

TypeDirect peer
Description

Sister Vant under Roivant Sciences developing targeted therapies for severe autoimmune disease. Shares the same operational model, parent backing, and therapeutic focus, making it the closest comparable in terms of organizational structure and strategic intent.

TypeEmerging player
Description

Clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Comparable in focus area and development stage, though with a more specialized cell therapy modality versus Kinevant's broader approach.

TypeEmerging player
Description

Clinical-stage biotechnology company developing therapeutics for rare diseases including autoimmune indications. Comparable as a similarly-sized emerging player in the rare autoimmune space with similar development-stage risk profile.

TypeDirect peer
Description

Biopharmaceutical company focused on autoimmune diseases, particularly type 1 diabetes (acquired by Sanofi in 2023). Comparable as a rare autoimmune disease developer that achieved successful commercialization and exit, relevant precedent for Kinevant's trajectory.

TypeBroad incumbent
Description

Major pharmaceutical company with significant autoimmune disease franchise including HUMIRA and SKYRIZI. Relevant as a potential acquirer and benchmark for commercial scale in autoimmune therapeutics that Kinevant could eventually partner with or be acquired by.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kinevant Sciences

Rare Disease Biopharmaceuticalskinevant.com

Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and based in New York, dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs. It operates within the Roivant Vant ecosystem.

What Kinevant Sciences does

Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in New York, United States. The company is dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs, operating within the Roivant Sciences ecosystem as one of its "Vants" — a structural model designed to create agile, focused subsidiaries with aligned incentives for efficient drug development and rigorous capital allocation.

The company's core focus is the discovery and development of therapeutic candidates for rare autoimmune conditions, though specific drug candidates, mechanisms of action, target indications, or clinical trial programs are not disclosed in the available data. As a clinical-stage entity, Kinevant does not yet have commercialized products, and its underlying technology and scientific approach are not explicitly described in the input material. The company leverages the Roivant parent's technology-enabled discovery, development, and commercialization infrastructure.

Kinevant operates with a very small team of 1-10 employees, consistent with an early-stage, asset-focused development model typical of clinical-stage biotech subsidiaries. Its business model is pre-commercial, with no disclosed revenue, pricing, or customer base. Economics are expected to depend on advancing therapeutic candidates through regulatory milestones, potentially benefiting from orphan drug exclusivity given the rare disease focus. Funding flows through the Roivant parent and its capital allocation framework rather than through independently disclosed rounds.

Kinevant Sciences firmographics

Firmographics
Name
Kinevant Sciences
Website
https://kinevant.com
Company type
Private
Founded year
2019
Headcount range
1–10 employees
Short description
Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and based in New York, dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs. It operates within the Roivant Vant ecosystem.
Ownership category
akta.pro rank

Kinevant Sciences industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Autoimmune disease drugs
  • Clinical-stage biopharmaceuticals
  • Biopharmaceutical R&D
  • Specialty pharmaceuticals

Where Kinevant Sciences is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Kinevant Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Kinevant Sciences product offering

Product offering

Core offering

Kinevant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for rare autoimmune diseases with significant unmet medical needs. As a subsidiary "Vant" under Roivant Sciences, it focuses its pipeline on rare autoimmune indications, leveraging Roivant's technology-enabled discovery, development, and commercialization capabilities. The company is currently pre-commercial and operates with 1-10 employees.

Differentiator

Problem solved

Functional benefit

Companies that use Kinevant Sciences

Customer profile

Ideal customer profiles2 records

Kinevant Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kinevant Sciences partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Kinevant Sciences competitors and assessment

Company assessment

Emerging players

  • AnaptysBio: Clinical-stage biotechnology company developing inflammation and autoimmune therapeutics, including IL-36 and checkpoint agonist antibodies. Comparable in therapeutic focus area and clinical-stage development profile.
  • Viridian Therapeutics: Clinical-stage biotechnology company developing therapeutics for autoimmune diseases, particularly in rare endocrinology and ophthalmology. Comparable in targeting rare autoimmune indications and operating at a similar development stage.
  • Immunic Therapeutics: Clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. Comparable as a similarly-sized clinical-stage company targeting autoimmune indications with similar binary risk profile.
  • Caballeta Bio: Clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Comparable in focus area and development stage, though with a more specialized cell therapy modality versus Kinevant's broader approach.
  • Arcturus Therapeutics: Clinical-stage biotechnology company developing therapeutics for rare diseases including autoimmune indications. Comparable as a similarly-sized emerging player in the rare autoimmune space with similar development-stage risk profile.

Direct peers

  • Immunovant: Sister Vant under Roivant Sciences focused on autoimmune diseases. Most directly comparable as it shares the same platform model, parent company, and therapeutic focus area, but operates at a more advanced stage with publicly disclosed clinical assets.
  • Chemocentryx: Biopharmaceutical company focused on autoimmune and inflammatory diseases (acquired by Amgen in 2022). Comparable as a company that successfully developed and commercialized rare autoimmune disease therapeutics, illustrating a potential exit pathway for Kinevant.
  • Priovant Therapeutics: Sister Vant under Roivant Sciences developing targeted therapies for severe autoimmune disease. Shares the same operational model, parent backing, and therapeutic focus, making it the closest comparable in terms of organizational structure and strategic intent.
  • Provention Bio: Biopharmaceutical company focused on autoimmune diseases, particularly type 1 diabetes (acquired by Sanofi in 2023). Comparable as a rare autoimmune disease developer that achieved successful commercialization and exit, relevant precedent for Kinevant's trajectory.

Broad incumbents

  • AbbVie: Major pharmaceutical company with significant autoimmune disease franchise including HUMIRA and SKYRIZI. Relevant as a potential acquirer and benchmark for commercial scale in autoimmune therapeutics that Kinevant could eventually partner with or be acquired by.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Kinevant Sciences social profiles

Digital presence

Kinevant Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kinevant Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Kinevant Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kinevant Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinevant Sciences

What does Kinevant Sciences do?

Kinevant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for rare autoimmune diseases with significant unmet medical needs. As a subsidiary "Vant" under Roivant Sciences, it focuses its pipeline on rare autoimmune indications, leveraging Roivant's technology-enabled discovery, development, and commercialization capabilities. The company is currently pre-commercial and operates with 1-10 employees.

When was Kinevant Sciences founded?

Kinevant Sciences was founded in 2019. It employs 1 to 10 people.

Where is Kinevant Sciences based?

Kinevant Sciences is headquartered in New York, United States, in the North America region.

Who are Kinevant Sciences's main competitors?

Emerging players on record are AnaptysBio, Viridian Therapeutics, Immunic Therapeutics, Caballeta Bio and Arcturus Therapeutics. Direct peers are Immunovant, Chemocentryx, Priovant Therapeutics and Provention Bio. AbbVie is listed as a broad incumbent.

Does Kinevant Sciences have an API?

No public API is recorded for Kinevant Sciences.

What industry is Kinevant Sciences in?

Kinevant Sciences's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals